Loading…

Schrodinger, Inc.SDGRCompetitor analysis, valuation and peers

United States · USD·Information Technology›Packaged Software

Sells physics-based molecular simulation software for drug and materials discovery, and develops its own drug pipeline.

Momentum leader 98
Mkt cap
$2.04B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$47.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 13.1%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$27.20
1D+6.0%
1W-13.7%
1M+16.2%
3M+37.0%
6M+126.9%
YTD+52.1%
1Y+54.2%
ATR %9.0%
Beta1.55
52w lowhigh20.0% off high

What Schrodinger does

Sells physics-based molecular simulation software for drug and materials discovery, and develops its own drug pipeline.

Software licences, mostly annual and sold to drug and materials researchers, are the steady line. A second line earns collaboration payments and milestones from partners using its methods, while its own drug programmes add uncertain, lumpy income.

Products and services

  • Molecular simulation/computational chemistry software
  • Drug discovery collaborations (pharma partners)
  • Proprietary drug development pipeline

Customers

  • Pharmaceutical/biotech companies
  • Materials science companies

Where it sits in the supply chain

  • Information technology
  • Life sciences software/biotech
  • Computational drug discovery software…

What could go right

  • Growing pharma computational drug discovery adoption
  • Software platform licensing/collaboration revenue growth

What could go wrong

  • Drug pipeline clinical trial failure risk
  • Pharma R&D budget cyclicality

Moat: narrow (IP / patents, process know-how, data). Decades of physics-based simulation technology create a technical edge, but the drug pipeline adds binary risk.

Headquarters: New York, New York, United States · Founded: 1990 · Employees: 850

Named competitors

Schrodinger at a glance

Size Schrodinger (SDGR) is a United States Information Technology company (Packaged Software) with a market value of $2.04B, the 1760th largest of 3,085 United States companies the cockpit tracks. Shares closed at $27.20 on 18 Nov 2026.

Performance Over six months the shares gained 126.9%, against +19.6% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 4.8% over the last twelve months (peer median +21.1%); the operating margin is -49.6% (peer median 4.7%).

Valuation It trades at 6.6× enterprise value to sales against a peer median of 3.9× (4th most expensive of 20).

Backlog Backlog (remaining performance obligations) was $187M at 30 Sep 2026, up 251% on a year earlier — 0.7 years of trailing revenue. Backlog detail →

Short interest Short interest is 14.8% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10020021 May 202621 Aug 202618 Nov 2026SDGR 221Peer median 117
Six months, rebased to 100: Schrodinger against the median of its 20 peers (local-currency closes).

Schrodinger financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$269M$256M$208M$217M$181M
Revenue growth—+23%-4%+20%—
Gross profit$158M$143M$132M$140M$101M
EBITDA-$128M-$161M-$203M-$172M-$142M
Net income-$59.3M-$103M-$187M$40.7M-$149M
Free cash flow-$117M$12.5M-$165M-$2.92M-$116M
Capital expenditure$4.20M$1.44M$7.31M$13.4M$8.01M
Total debt$105M$109M$118M$128M$116M

Quarterly statements and history in the cockpit →

Schrodinger competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-10%0%+10%PBIEMBRAC-B688343002405PINELABS688507ASANLIFEDV13571860NYAXAMPL4686603171SHADOWFAX3923688158KAROSDGR6-month return →1-month return →
Up and to the right = strong over both horizons. Schrodinger is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×10×20×PBIEMBRAC-B688343002405688507ASANLIFE13571860NYAXAMPL4686603171SHADOWFAX688158300738SDGRRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Schrodinger is the large dot.

Schrodinger competitors and peer comparison

Head to head with its named competitors (SDGR vs CERT vs RXRX vs RLAY)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Schrodinger SDGR$2.04B+127%+5%-50%6.6×n/a
Certara CERT$1.71B+139%-4%4%4.5×40.1%
Recursion Pharmaceuticals RXRX$1.76B-5%+56%-725%18.8×n/a
Relay Therapeutics RLAY$3.65B+27%+24%-3,095%273.1×n/a

How Schrodinger compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Schrodinger against its 20 peers (data as of 18 Nov 2026)
MeasureSDGRPeer medianRank in peer set
1-month return+16.2%-2.9%highest of 21
6-month return+126.9%+19.6%2nd highest of 21
Distance from 52-week high-20.0%-37.3%7th highest of 21
Revenue growth (TTM)+4.8%+21.1%4th lowest of 21
Operating margin-49.6%4.7%2nd lowest of 21
EV / Sales6.6×3.9×4th most expensive of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Schrodinger SDGRUnited States$2.04B+127%+5%-50%6.6×n/an/a
Pitney Bowes PBIUnited States$2.06B-1%-4%25%2.0×-5.5%-11.8%
Embracer EMBRAC-B.STSweden$2.06B+36%-14%-42%1.1×-10.8%+12.0%
Shenzhen Intellifusion Technologies 688343.SSChina$2.01B-34%-4%-52%9.2×n/an/a
SeeWay.ai 002405.SZChina$2.08B-33%+22%-29%3.1×n/an/a
Pine Labs PINELABS.NSIndia$2.09B+13%+50%7%n/an/an/a
Shanghai Suochen Information Technology 688507.SSChina$1.98B+45%+32%-2%22.8×n/an/a
Asana ASANUnited States$2.11B+39%+9%-15%2.4×8.4%+28.4%
Ethos Technologies LIFEUnited States$2.12B+63%+112%-16%2.6×24.8%n/a
DoubleVerify DVUnited States$2.12B+45%+7%14%2.5×10.1%+25.1%
Meitu 1357.HKHong Kong$2.13B-19%+24%24%2.9×4.2%+25.5%
Mobvista Incorporation 1860.HKHong Kong$1.94B-36%+26%4%0.8×-1.8%+31.9%
Nayax NYAXUnited States$1.94B-24%+20%4%3.9×34.3%+38.7%
Amplitude AMPLUnited States$2.15B+160%+20%-25%5.1×36.7%+27.4%
Justsystems 4686.TJapan$1.91B+26%+5%45%3.5×-7.2%+4.6%
Servyou Software 603171.SSChina$2.20B-35%+6%5%6.4×34.8%+5.9%
Shadowfax Technologies SHADOWFAX.NSIndia$1.88B+58%+69%10%4.0×48.1%+43.7%
RAKUS 3923.TJapan$2.23B+26%+10%33%5.8×14.9%+31.4%
UCloud Technology 688158.SSChina$1.87B-39%+26%2%6.1×n/an/a
Guangdong Aofei Data Technology 300738.SZChina$2.23B-42%+24%23%8.8×n/an/a
Karooooo KAROUnited States$1.86B+28%+32%25%5.2×10.0%+17.7%

Schrodinger backlog

Schrodinger reported $187M of remaining performance obligations at 30 Sep 2026, up 251% from a year earlier and down 1% from the previous quarter. That is 0.7 years of trailing revenue already under contract. Book-to-bill last quarter: 0.96.

Questions

Who are Schrodinger's main competitors?
Named competitors: Certara (CERT), Recursion Pharmaceuticals (RXRX), Relay Therapeutics (RLAY). The cockpit's measured peer set (industry) also includes Pitney Bowes (PBI), Embracer (EMBRAC-B.ST), Shenzhen Intellifusion Technologies (688343.SS), SeeWay.ai (002405.SZ), Pine Labs (PINELABS.NS), Shanghai Suochen Information Technology (688507.SS).
Is Schrodinger expensive compared with its peers?
On ev / sales it trades at 6.6× against a peer median of 3.9×, 4th most expensive of 20 in its peer set.
How has Schrodinger stock performed?
Over six months to 18 Nov 2026 the shares returned +126.9% against +19.6% for the median peer; over one year +54.2%.
What is Schrodinger's backlog?
Schrodinger's remaining performance obligations (contracted revenue not yet recognised) were $187M at 30 Sep 2026, +251% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.